Product nameAnti-Collagen IV antibody
See all Collagen IV primary antibodies
DescriptionRabbit polyclonal to Collagen IV
Specificityab6586 is designed to bind specifically to NATIVE collagen epitopes composed of multiple subunit strands. Negligible cross-reactivity with Type I, II, III, V or VI collagens. Non-specific cross reaction of anti-collagen antibodies with other human serum proteins or non-collagen extracellular matrix proteins is negligible.
Tested applicationsSuitable for: ELISA, IHC-Fr, IP, WB, ICC/IF, IHC-P, IHC-FrFl, IHC-FoFrmore details
Species reactivityReacts with: Mouse, Rat, Hamster, Cow, Dog, Human, Pig, Zebrafish, African green monkey, Chinese hamster, Syrian hamster
Predicted to work with: Mammals
Full length native protein (purified) corresponding to Collagen IV. Collagen Type IV from human and bovine placenta. The immunogen maintains the native conformation of the protein.
- Natural Human Collagen IV protein (ab7536) can be used as a positive control in WB. human epidermal keratinocytes lysate
At least 11 genetically distinct gene products are collectively referred to as 'collagen types' or other proteins and proteoglycans of the extracellular matrix. In humans, collagens are composed of about 20 unique protein chains which under go various types of post-translational modifications and are ultimately assembled into a triple helix. This results in great diversity between collagen types. Collagens are highly conserved throughout evolution and are characterized by an uninterrupted "Glycine-X-Y" triplet repeat that is a necessary part of the triple helical structure. For these reasons it is often extremely difficult to generate antibodies with specificities to collagens. The development of type specific antibodies is dependent on NON-DENATURED three-dimensional epitopes. This preparation results in a native conformation of the protein.
This antibody is well suited to detect extracellular matrix proteins in normal as well as disease state tissues. Disruption of tissue organization is the hallmark of neoplasia. Malignant lesions can be distinguished from benign by examining the breakdown of basement membranes and loss of 3-dimensional architecture. Malignant cells are presumed to use matrix metalloproteases to degrade barriers created by the extracellular matrix which then allows metastasis to occur. Collagenases, stomelysins and gelatinases can collectively degrade all of the various components of the extracellular matrix, including fibrillar and non-fibrillar collagens and basement membrane glycoproteins.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 8.00
Preservative: 0.01% Sodium azide
Constituents: 4.7625% Sodium borate, 0.146% EDTA, 0.435% Sodium chloride
Concentration information loading...
PurityImmunogen affinity purified
Purification notesImmunoaffinity chromatography using immobilized antigens followed by extensive cross-adsorption against other collagens, human serum proteins and non-collagen extracellular matrix proteins to remove any unwanted specificities.
Primary antibody notesThis antibody is well suited to detect extracellular matrix proteins in normal as well as disease state tissues. Disruption of tissue organization is the hallmark of neoplasia. Malignant lesions can be distinguished from benign by examining the breakdown of basement membranes and loss of 3-dimensional architecture. Malignant cells are presumed to use matrix metalloproteases to degrade barriers created by the extracellular matrix which then allows metastasis to occur. Collagenases, stomelysins and gelatinases can collectively degrade all of the various components of the extracellular matrix, including fibrillar and non-fibrillar collagens and basement membrane glycoproteins.
Our Abpromise guarantee covers the use of ab6586 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||1/5000 - 1/50000.|
|IHC-Fr||1/50 - 1/200.|
|WB||1/1000 - 1/10000. Use under non reducing condition. This product is not recommended for use under denaturing conditions in WB, IP, and ELISA. We would suggest testing it under native conditions.|
|ICC/IF||Use at an assay dependent concentration. PubMed: 19933193|
|IF||Use at an assay dependent concentration. PubMed: 28153846|
|IHC-P||1/500. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
|IHC-FrFl||Use at an assay dependent concentration.|
|IHC-FoFr||Use at an assay dependent concentration.|
FunctionType IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen.
Arresten, comprising the C-terminal NC1 domain, inhibits angiogenesis and tumor formation. The C-terminal half is found to possess the anti-angiogenic activity. Specifically inhibits endothelial cell proliferation, migration and tube formation. Inhibits expression of hypoxia-inducible factor 1alpha and ERK1/2 and p38 MAPK activation. Ligand for alpha1/beta1 integrin.
Tissue specificityHighly expressed in placenta.
Involvement in diseaseDefects in COL4A1 are a cause of brain small vessel disease with hemorrhage (BSVDH) [MIM:607595]. Brain small vessel diseases underlie 20 to 30 percent of ischemic strokes and a larger proportion of intracerebral hemorrhages. Inheritance is autosomal dominant.
Defects in COL4A1 are the cause of hereditary angiopathy with nephropathy aneurysms and muscle cramps (HANAC) [MIM:611773]. The clinical renal manifestations include hematuria and bilateral large cysts. Histologic analysis revealed complex basement membrane defects in kidney and skin. The systemic angiopathy appears to affect both small vessels and large arteries.
Defects in COL4A1 are a cause of porencephaly familial (PCEPH) [MIM:175780]. Porencephaly is a term used for any cavitation or cerebrospinal fluid-filled cyst in the brain. Porencephaly type 1 is usually unilateral and results from focal destructive lesions such as fetal vascular occlusion or birth trauma. Type 2, or schizencephalic porencephaly, is usually symmetric and represents a primary defect or arrest in the development of the cerebral ventricles.
Sequence similaritiesBelongs to the type IV collagen family.
Contains 1 collagen IV NC1 (C-terminal non-collagenous) domain.
DomainAlpha chains of type IV collagen have a non-collagenous domain (NC1) at their C-terminus, frequent interruptions of the G-X-Y repeats in the long central triple-helical domain (which may cause flexibility in the triple helix), and a short N-terminal triple-helical 7S domain.
modificationsLysines at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in all cases and bind carbohydrates.
Prolines at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains.
Type IV collagens contain numerous cysteine residues which are involved in inter- and intramolecular disulfide bonding. 12 of these, located in the NC1 domain, are conserved in all known type IV collagens.
The trimeric structure of the NC1 domains is stabilized by covalent bonds between Lys and Met residues.
Proteolytic processing produces the C-terminal NC1 peptide, arresten.
Cellular localizationSecreted > extracellular space > extracellular matrix > basement membrane.
- Information by UniProt
- Arresten antibody
- BSVD antibody
- CO4A1_HUMAN antibody
Paraffin-embedded human kidney tissue stained for Collagen IV using ab6586 at 1/400 dilution in immunohistochemical analysis with strong staining observed in glomeruli.
Paraffin-embedded human liver tissue stained for Collagen IV using ab6586 at 1/400 dilution in immunohistochemical analysis, strong staining was observed in the sinusoids.
ab6586 staining Collagen IV in Dog liver tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 5% serum for 30 minutes at 25°C; antigen retrieval was by heat mediation in a 10mM citrate buffer, pH 6.0. Samples were incubated with primary antibody (1/200 in PBS + 1x casein) for 1 hour at 37°C. An undiluted HRP-conjugated Horse anti-rabbit IgG polyclonal was used as the secondary antibody.
Immunocytochemical analysis of Mouse 3T3 cell labeling Collagen IV with ab6586 at 1/250 dilution
Anti-Collagen IV antibody (ab6586) at 1/1000 dilution + Baby Hamster Kidney fibroblasts at 100 µg
HRP-conjugated donkey anti-rabbit polyclonal IgG
at 1/4000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Observed band size: 300 kDa why is the actual band size different from the predicted?
Exposure time: 10 seconds
Blocked with 5% milk
ab6586 staining rat brain tissue sections (ab4616) by IHC-Fr. Sections were acetone fixed and blocked with 1% serum for 20 minutes at 25°C. The primary antibody was diluted 1/300 and incubated with the sample for 30 minutes at 25°C. A biotinylated goat anti-rabbit IgG antibody was used as the secondary.
ab6586 staining Collagen IV in heart tissue by Immunohistochemistry (Frozen sections). The sections were fixed in Acetone prior to blocking with 100% SuperBlock Blocking Buffer for 20 mins at 23°C. The primary antibody was diluted 1/50 and incubated with the sample for 12 hours at 4°C. ab6720 was used as the secondary antibody, diluted 1/100.
ab6586 staining Collagen IV in pig epithelial tissue by Immunohistochemistry (Frozen sections).
Tissue was fixed in acetone then incubated with ab6586 at a 1/200 dilution for 1 hour at 25°C. The secondary used was ab96886, a goat polyclonal to rabbit IgG - H&L (DyLight® 649), used at a 1/500 dilution.
This product has been referenced in:
- Narumi K et al. (Pro)renin receptor is involved in mesangial fibrosis and matrix expansion. Sci Rep 8:16 (2018). Read more (PubMed: 29311647) »
- Vermeulen M et al. Development of a Cytocompatible Scaffold from Pig Immature Testicular Tissue Allowing Human Sertoli Cell Attachment, Proliferation and Functionality. Int J Mol Sci 19:N/A (2018). Read more (PubMed: 29329231) »